Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
CNBC Stocks· Aug 4, 2026 · 10:34 AM
Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
This is a summary. Read the complete story at CNBC Stocks below.
Read full article at CNBC Stocks
